151 related articles for article (PubMed ID: 18371508)
1. Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.
Vartany E; Caldwell CA; Trow TK
Heart Lung; 2008; 37(2):153-6. PubMed ID: 18371508
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L
J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434
[No Abstract] [Full Text] [Related]
3. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.
Abi-Nassif S; Mark EJ; Fogel RB; Hallisey RK
Chest; 2003 Jul; 124(1):406-10. PubMed ID: 12853555
[TBL] [Abstract][Full Text] [Related]
5. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
Manz M; Steuerwald M
Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
[TBL] [Abstract][Full Text] [Related]
6. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
Mahajan S; Avasthi A; Grover S; Chawla YK
J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis C therapy is not pleasant. Patients must be prepared!].
MMW Fortschr Med; 2003 Jan; 145(3-4):57. PubMed ID: 12619237
[No Abstract] [Full Text] [Related]
9. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
Condat B; Asselah T; Zanditenas D; Estampes B; Cohen A; O'Toole D; Bonnet J; Ngo Y; Marcellin P; Blazquez M
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):287-9. PubMed ID: 16462543
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports.
Hegade VS; Sood R; Saralaya D; Moreea S
Ann Hepatol; 2013; 12(4):629-33. PubMed ID: 23813142
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
Vujosevic S; Tempesta D; Noventa F; Midena E; Sebastiani G
Hepatology; 2012 Aug; 56(2):455-63. PubMed ID: 22331668
[TBL] [Abstract][Full Text] [Related]
12. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
13. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Halász T; Farkas A; Tolvaj G; Horváth G
Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
[TBL] [Abstract][Full Text] [Related]
14. [Interferon therapy for hepatitis B and C].
Iino S
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():559-63. PubMed ID: 17455681
[No Abstract] [Full Text] [Related]
15. Rosacea fulminans related to pegylated interferon alpha-2b and ribavirin therapy.
Bettoli V; Mantovani L; Boccia S; Virgili A
Acta Derm Venereol; 2006; 86(3):258-9. PubMed ID: 16710591
[No Abstract] [Full Text] [Related]
16. Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C.
Golstein PE; Delforge ML; Deviere J; Marcellin P
J Viral Hepat; 2004 Mar; 11(2):183-6. PubMed ID: 14996354
[TBL] [Abstract][Full Text] [Related]
17. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
18. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
[TBL] [Abstract][Full Text] [Related]
19. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
[No Abstract] [Full Text] [Related]
20. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chen YC; Lu SN; Lin MC
Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
